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Abstract 
Background: Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients 
show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult 
for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater preci‑
sion in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need.
Structure: The H2020‑funded Response to Lithium Network (R‑LiNK; hiip://www.r ‑link.eu.com/) will undertake a pro‑
spective cohort study of over 300 individuals with bipolar‑I‑disorder who have agreed to commence a trial of lithium 
treatment following a recommendation by their treating clinician. The study aims to examine the early prediction of 
lithium response, non‑response and tolerability by combining systematic clinical syndrome subtyping with examina‑
tion of multi‑modal biomarkers (or biosignatures), including omics, neuroimaging, and actigraphy, etc. Individuals will 
be followed up for 24 months and an independent panel will assess and classify each participants’ response to lithium 
according to predefined criteria that consider evidence of relapse, recurrence, remission, changes in illness activity or 
treatment failure (e.g. stopping lithium; new prescriptions of other mood stabilizers) and exposure to lithium. Novel 
elements of this study include the recruitment of a large, multinational, clinically representative sample specifically for 
the purpose of studying candidate biomarkers and biosignatures; the application of lithium‑7 magnetic resonance 
imaging to explore the distribution of lithium in the brain; development of a digital phenotype (using actigraphy and 
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Background
Across medical disciplines, there is increasing recogni-
tion of the potential utility of personalized or precision 
diagnostics and therapeutics. Although there are subtle 
differences in the meaning of terms such as ‘personal-
ized’ and ‘precision’ medicine, the approaches share the 
same goal, namely to tailor clinical decision-making to 
each patient by utilizing information about individual 
phenotypes and genotypes (European Commission 
2011). In psychiatry, it is unlikely that personalized 
diagnostics will be developed for some time as there is 
uncertainty regarding pathophysiological mechanisms 
underpinning different mental disorders and no objec-
tive laboratory tests are available (Perna et  al. 2018; 
Schumann et  al. 2014). However, it may be feasible 
to help clinicians to customise psychiatric treatment 
decisions by applying the principles of precision medi-
cine and stratifying patients according to likelihood 
of response (Scott and Etain 2018). Several multicen-
tre collaborations exist that are fully or partly focused 
on the identification of biomarkers of psychotropic 
response, including ongoing studies of antidepressant 
response (Trivedi et al. 2016); of selected subgroups of 
patients with bipolar disorders (BD) recruited to ran-
domized controlled trials (RCTs) (Ritter et  al. 2016); 
and of pharmacogenomics of lithium (Li) response 
(Oedegaard et  al. 2016). The Response to Li Network 
(R-LiNK; https ://rlink .eu.com/) is a new European ini-
tiative aimed at exploring precision prescribing of Li in 
BD-I; this project will complement other studies and 
address some of the gaps in current knowlegde.
In this preliminary communication, we highlight the 
rationale for developing this prospective multidiscipli-
nary international project, then we provide a brief synop-
sis of the planned study and comment on the important 
opportunities and potential difficulties of undertaking 
this type of multicentre research.
The Rationale for R‑LiNK
The BD diagnostic category comprises a broad range of 
disorders affecting about 1–3% of the global population. 
Whilst the diagnosis of BD-II and other bipolar spectrum 
disorders show poor reliability, BD-I is one of the three 
most reliable diagnoses in psychiatry and this BD subtype 
has superior predictive validity for future disease course 
and outcome (First 2016). In its most severe form, BD-I is 
associated with considerable morbidity, all-cause prema-
ture mortality and a high risk of suicide (Whiteford et al. 
2013). Further, a recent study from the USA estimated 
that the economic burden of BD-I exceeded $200 billion, 
a cost which Cloutier et al. (2018) suggest illustrates the 
need to optimize therapeutic strategies. This view con-
curs with the European College of Neuropsychopharma-
cology Network Initiative and the European Medicines 
Agency, which both advocate for international, collabo-
rative research to promote individualized prescribing of 
established and novel drug treatments in BD.
A critical component of the treatment of BD-I is pre-
vention of relapse/recurrence and reduction in suicidal-
ity (Kessing et  al. 2018; Tondo and Baldessarini 2018). 
Clinical and research evidence suggests that Li is one 
of the most efficacious interventions for targeting these 
problems and can be beneficial in treating acute BD epi-
sodes (Bauer et al. 2018; Vieta et al. 2018). Also, it is the 
least expensive mood stabilizer available, with a 1-month 
supply of Li costing only about one dollar (Oedegaard 
et  al. 2016). However, there are difficulties in translat-
ing research efficacy of Li into clinical effectiveness in 
BD-I. For example, response to Li in acute mania does 
not reliably predict the outcome of prophylactic treat-
ment; many individuals report tolerability issues; and the 
narrow therapeutic window leads to concerns regarding 
toxicity (Hayes et  al. 2016; Kessing et  al. 2018). These 
problems have all reduced patient and clinician prefer-
ence for Li as a first line treatment (Zivanovic 2017). 
ecological momentary assessment) to monitor daily variability in symptoms; and economic modelling of the cost‑
effectiveness of introducing biomarker tests for the customisation of lithium treatment into clinical practice. Also, 
study participants with sub‑optimal medication adherence will be offered brief interventions (which can be delivered 
via a clinician or smartphone app) to enhance treatment engagement and to minimize confounding of lithium non‑
response with non‑adherence.
Conclusions: The paper outlines the rationale, design and methodology of the first study being undertaken by the 
newly established R‑LiNK collaboration and describes how the project may help to refine the clinical response pheno‑
type and could translate into the personalization of lithium treatment.
Keywords: Bipolar, Precision, Personalization, Lithium, Response, Phenotype, Digital, Actigraphy, Omics, 
Neuroimaging
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Overall, the trial and error approach to prescribing Li for 
relapse prevention in clinical settings means that its real-
world effectiveness is only about half of that reported 
in research settings and partial- or non-adherence is an 
important contributor to this treatment failure (Scott and 
Pope 2002; Howes et al. 2017).
Given the above, it is unsurprising that psychiatrists, 
patients and their significant others would welcome a 
more customised approach to prescribing Li prophy-
laxis in BD-I. Most importantly, there is a need to avoid 
or considerably curtail the extended trial period (about 
18–24  months) that is often required to determine 
whether there has been a significant reduction in the 
frequency and severity of relapses/recurrences or a clini-
cally meaningful decrease in illness activity. To date, pre-
dictors of Li response employed in clinical practice are 
contradictory and biomarkers of prophylactic response 
or tolerability remain tenuous (Kleindienst et  al. 2005; 
Sportiche et al. 2017; Oedegaard et al. 2016; Montlahuc 
et  al. 2019). However, experts involved in clinical and 
research work with individuals with BD-I have recently 
reported encouraging preliminary findings regard-
ing response predictors across a range of domains such 
as omics and neuroimaging (e.g. Silverstone et  al. 2005; 
Hallahan et al. 2011; Bellivier et al. 2013; Roux and Dos-
seto 2017; Smith et al. 2018). Following discussions, they 
agreed that several candidate biomarkers of Li response 
warranted further study. However, the prerequisites for 
further research were (a) access to large clinically repre-
sentative samples, and (b) a more systematic ‘integrative 
science’ approach to examination of clinical response 
phenotypes (comprising clinical syndrome subtyping and 
prospective longitudinal monitoring of course of illness 
during exposure to treatment), and the selected func-
tional, structural, and molecular or metabolic biomarkers 
(Amare et al. 2017). Sixteen European centres (see Addi-
tional file 1: Appendix S1) have formed a multi-national 
research collaboration focused on the study of the Li 
response in BD-I. The network aims to provide a basis 
for precision prescribing of Li and address some of the 
potential methodological issues highlighted by research-
ers involved in analogous studies (see Table 1 for exam-
ples of reported issues and R-LiNK approach).
The development of R-LiNK and the current project 
are funded via the H2020 funding stream on personalized 
medicine (https ://cordi s.europ a.eu/proje ct/rcn/21267 6/
facts heet/en). Another benefit of the collaboration is that 
it provides an infrastructure to support future multidisci-
plinary, multicentre research on personalized diagnostics 
and therapeutics for BD. Also, the network will receive 
input and feedback from a committee of international 
experts that monitors and advises on the project. From 
the start, R-LiNK has fostered links to researchers and 
initiatives involved in similar studies (e.g. Schulze et  al. 
2010; Oedegaard et  al. 2016), which also may facilitate 
data sharing.
Synopsis of the R‑LiNK cohort study
The inaugural R-LiNK project comprises a prospective 
cohort study and the protocol follows STROBE guide-
lines (Strengthening the Reporting of Observational 
Studies in Epidemiology; von Elm et al. 2007); its two key 
objectives are:
 (i) To improve the early prediction of response to Li 
by identifying multi-modal biomarkers or biosigna-
tures;
 (ii) To implement new and powerful technologies, 
such as functional omics (genetics, transcriptom-
ics, metabolomics, etc.), to help characterize the 
early molecular signature of Li in responders and 
non-responders; also, selected centres will use 
lithium-7 magnetic resonance imaging (7Li-MRI) 
to characterize the early steady state distribution of 
Li in the brain (and examine differences associated 
with responder status).
The project comprises of several work packages 
(WP), each of which has specific objectives or tasks (see 
Table  2). For instance, WP4 includes MRI of specific 
brain structures (e.g. amygdala) and metabolic imag-
ing (using proton magnetic resonance spectroscopy 
(1H-MRS)) undertaken pre- and post-initiation of Li; 
whilst WP9 focuses on communication, dissemination 
and exploitation of findings. Most WP warrant separate 
articles to fully describe the underlying hypotheses and 
strategies, so this preliminary communication provides a 
brief overview of the planned study, highlighting selected 
components.
The study is being undertaken in accordance with the 
Revised Declaration of Geneva (Parsa-Parsi 2017). Ethi-
cal approval was first obtained in France (18.08.02.40026 
RiPH 2), followed by approval by ethics committees in 
other participating countries. Recruitment of study partic-
ipants commences during 2019, but such a large-scale col-
laborative venture requires considerable preparatory work 
(see WP1 and WP2). So, 2018 was dedicated to establish-
ing management structures; developing and translating 
clinical assessments; establishing inter-rater reliability; 
harmonization of study protocols between centres (e.g. for 
MRI); developing procedures for collection and transpor-
tation of blood samples; construction of shared database; 
establishing study monitoring procedures; etc.
A priority for the project is to maximize the clini-
cal representativeness of the cohort by offering study 
participation to consecutive cases of BD-I that have 
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agreed to commence a trial of Li (WP3). Each centre 
will recruit approximately 20 patients (with replace-
ment of early dropouts), but the sample size calculation 
has allowed for 10–20% attrition during follow-up. To 
increase the translational potential of the study, there 
are only three eligibility criteria, namely that a poten-
tial participant has: (i) a diagnosis of BD-I confirmed 
according to internationally recognized diagnostic cri-
teria (American Psychiatric Association 2013); (ii) no 
known reason for exclusion from the research (i.e. the 
individual is willing and able to give written informed 
consent; there is no imminent risk of severe self-harm; 
etc.); and (iii) no contra-indication to taking Li is iden-
tified by the treating clinician or during preliminary 
clinical and physiological screening. As several linked 
sub-studies are being undertaken, it is important to 
consider participant burden, so patients can opt to 
consent to involvement in some but not all sub-stud-
ies. Likewise, some centres will focus their research 
endeavours of the measurement of specific biomarkers, 
e.g. some but not all centres will perform 7Li-MRI or 
collect actigraphy data, etc.
The R-LiNK centres have been discouraged from 
changing their approach to Li prescribing and clini-
cal case management will be undertaken separately 
and independently of the research protocol. Clinicians 
involved in the day-to-day treatment of patients will 
make all decisions regarding initiation and prescrip-
tion of Li, dose titration and continuation or discon-
tinuation of prophylaxis according to individual patient 
needs.
As shown in Fig.  1, the first 12  weeks of the study 
involve a systematic, detailed baseline clinical assess-
ment (Additional file 2: Appendix S2 provides the list of 
proposed measures). This occurs alongside the stepwise 
measurement of structural, functional and molecular 
or metabolic biomarkers, which is undertaken before 
and 12 weeks after Li initiation to capture intra-indi-
vidual biological changes to be tested with the long-
term response status. This study phase is followed by 
Table 1 Summary of  approaches used by  current studies of  precision psychiatry compared with  the  R‑LiNK study (see 
text for details)
Current approach R-LiNK strategy
Studies of lithium response biomarkers are largely based on secondary 
analyses of efficacy RCTs, or convenience samples. The lack of clinical 
representativeness and/or small sample sizes may have contributed 
to biases in findings in biomarker studies (Carvalho et al. 2016; Hoertel 
et al. 2013)
To increase the translational potential, the R‑LiNK study employs a prag‑
matic design that reflects clinical reality. Each centre will recruit 20–30 
patients who have agreed to initiate a trial of lithium treatment (on 
the recommendation of their treating clinician). Exclusion criteria are 
minimized to enhance the generalizability and external validity of study 
findings
The definition and measurement of lithium response varies between 
publications. Some studies focus only on ‘good response’ subgroups 
and compare this group to the rest of the population; others identify 
several response categories or compare a range of categorical and 
continuous measures of response. Many studies assess lithium response 
using cross‑ sectional retrospective assessments rather than prospective 
monitoring. Also, only few studies follow guidelines on differentiating 
non‑response from non‑adherence (Howes et al. 2017)
R‑LiNK will follow participants prospectively for 2 years after initiation of 
lithium and will systematically assess clinical symptoms, illness activity 
and medication adherence over time. An independent panel of experts 
will examine all this longitudinal data to classify the clinical response of 
each participant according to response categories that have been agreed 
a priori (with the aim of reducing phenotypic misclassifications)
Lithium adherence and risk of sub‑optimal adherence will be monitored. 
A brief intervention may be offered to maintain engagement with treat‑
ment
Samples vary in homogeneity or heterogeneity, in the reliability of diag‑
nosis and the range of BD subtypes included
Measures of illness activity may vary significantly across studies: some use 
retrospective clinical reports, others use established observer ratings, 
others combine observer and objective ratings. The type of ratings 
selected, and the weightings given to individual symptoms of BD or to 
illness dimensions in the scales selected may affect the identification of 
clinical predictor variables or influence the concordance between clini‑
cal and biological variables
Few biomarker studies include patient‑related outcomes (PRO)
Many components of the methodology adversely affect the potential 
signal‑to‑noise ratio (South et al. 2017)
R‑LiNK will recruit individuals with symptoms that meet internationally 
accepted diagnostic criteria for BD‑I and includes methodological strate‑
gies that try to increase the ‘signal’ and reduce the ‘noise’ (Scott and Etain 
2018)
Symptom measures have been selected based on (i) good psychometric, 
item response theory (IRT) and clinimetric properties; (ii) the weighting 
given to symptoms that may be particularly sensitive to change early 
during lithium treatment (e.g. activity, energy and mood); (iii) a balanced 
assessment of key symptom dimensions
We will use electronic self‑monitoring of core BD symptoms. This ecological 
momentary assessment (EMA) approach will include daily ratings of a 
unique subset of selected symptoms of BD plus additional PRO items 
that can be used to formulate individualized ratings of personal recovery 
(which also can be compared with other R‑LiNK response categories)
Many studies focus on a single biomarker or select markers from one 
specific domain (e.g. focusing only on fMRI, omics, etc.). Recent research 
indicates that prediction may be enhanced by using combinations of 
factors, rather than trying to identify single or unidimensional biomark‑
ers of outcome or treatment response (Trivedi et al. 2016)
It is unlikely that there is a single biomarker for lithium response (or 
non‑response or tolerability), so R‑LiNK employs an integrative science 
approach to try to identify combinations of clinical, functional, structural, 
molecular and metabolic biomarkers (called biosignatures) that may be 
included in a composite prediction tool. In addition, R‑LiNK will examine 
clinical and biological moderators and mediators of lithium response
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prospective longitudinal clinical monitoring of illness 
activity, medication adherence and response to Li, with 
reassessments undertaken face to face every 3 months 
(supplemented by monthly telephone check-ups) for 
2 years.
Figure 1 highlights that some assessments and meas-
urements are undertaken only at baseline assessment 
(e.g. family history of mental disorders) whilst others 
are repeated before and after initiation of Li (e.g. blood 
is collected for omics studies to explore any early dif-
ferential molecular signatures of Li response; MRI is 
undertaken at baseline and at 12  weeks). In contrast, 
measurement of Li distribution in the brain is under-
taken only once at about 12  weeks); whilst there is 
an option for actigraphy to be continued over several 
months.
The R-LiNK project provides an opportunity to extend 
the search for phenotypes beyond the established archi-
types (Dawkins 1982). For instance, some centres will 
explore a putative digital phenotype of Li response in 
BD-I (a term that describes health data collected from 
individual monitoring, social media use, and measure-
ment of interactions with technology) (Jain et  al. 2015). 
This sub-study explores the combination of daily self-
ratings (e.g. mood, energy, activity) and continuous acti-
graphic recordings of sleep–wake cycles (Moskowitz and 
Young 2006; Faurholt-Jepsen et al. 2019; Scott et al. 2017). 
In keeping with patient and advocacy group requests, the 
electronic self-monitoring program allows participants to 
include additional self-selected patient-related outcomes 
(PRO) (Jonas et al. 2012). Also, a small-scale pilot study 
will explore self-monitoring and self-management using 
a prototype device that allows home-based measurement 
of salivary Li levels.
After all participants have completed the 2-year follow-
up period, an international panel of five experts will use 
a consensus approach to classify each case into the most 
appropriate response category (see Table  3 reports for 
selected details from the algorithm and an example of 
the proposed criteria for classifying Li response). First, 
the panel will classify cases according to change in illness 
activity (e.g. evidence of sustained remission or relapse/
recurrence that meet accepted criteria (Tohen et  al. 
2009)) irrespective of degree of exposure to Li across 
the 2-year prospective follow-up. At the second step, the 
panel will consider responder category in the context of 
real-world exposure to Li (dose and duration of Li treat-
ment, serum levels and medication adherence). This 
important issue is often overlooked in biomarker studies 
but may contribute to variance in findings or difficulties 
in interpretation of results (Scott and Pope 2002; Howes 
et  al. 2017). For example, it is possible that a good out-
come will be observed in some individuals who are Li 
non-adherent. This may confound responder analyses, as 
any biomarkers identified in this subgroup may be pre-
dictive of good prognosis in BD-I (independent of adher-
ence), rather than being associated with exposure to Li 
(Chen et  al. 2016; Hou et  al. 2016). Hence, in a similar 
way to the use of intent to treat and per protocol analy-
ses in RCTs, the use of these two strategies will allow the 





2 Set‑up, ethical approval, database development
3 Identification of baseline & follow‑up assessment of clinical symptoms, neuropsychological and social functioning, illness activity, etc
Characterisation of the clinical response phenotype for lithium treatment according to pre‑defined outcome measures (categorical/con‑
tinuous)
Assessment & optimization of medication adherence
Economic modelling of using a stratified approach to prescribing lithium; Qualitative & quantitative assessment of the digital phenotype
Development of a prototype device for salivary lithium measurement
4 Examination of neuro‑imaging (MRI and 1H‑spectroscopy) signature before & after lithium initiation to allow repeated assessment of e.g. 
architecture of the amygdala, etc
5 Assessment of 7Li‑MRI signature (i.e. distribution of lithium in the brain measured 12 weeks after initiation of treatment)
6 Blood sampling to measure omics (e.g. putative transcriptomic, mirnomic, methylomic and proteomic biomarkers) before & after lithium 
initiation to explore potential molecular signatures
7 Data management infrastructure for e.g. data collection of heterogeneous data (imaging, genetics, clinical) across different institutions & 
countries; Quality control of data processing; controlled data sharing; etc
Data analysis
8 Evaluation of laboratory to bedside transferability of study findings according to e.g. clinical feasibility, technical feasibility, utility of markers 
when employed alone or in combination (i.e. additivity or redundancy), acceptability & cost effectiveness
9 Communication & dissemination of findings
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panel to anticipate potential confounders of the clinically 
observed Li response in the R-LiNK cohort.
The study includes longitudinal assessment of medica-
tion adherence to help identify study participants with 
sub-optimal adherence and repeated measurement of 
relevant health beliefs should allow early identification of 
individuals at future risk of non-adherence (Clatworthy 
et al. 2009). The aspiration is to develop a brief, evidence-
based intervention to enhance medication adherence 
that can be delivered via a smartphone app or face-to-
face (Scott and Tacchi 2002).
Data management and analysis
The analyses of each biomarker (alone or in combination) 
will be guided by the approaches used by researchers 
involved in each WP. In R-LiNK, moderators of treat-
ment effects may include baseline clinical characteris-
tics, or markers derived from tests undertaken early in 
Li treatment (e.g. neuropsychology). Likewise, potential 
mediators of Li effects may include e.g. changes in omics 
or neuroimaging markers (measured prior to commenc-
ing Li and at 12 weeks).
Many researchers argue that discovery science strat-
egies are justifiable in precision psychiatry as these 
approaches are both hypothesis generating and hypoth-
esis-testing (e.g. Mennes 2016; Trivedi et al. 2016). This 
strategy has been proposed for R-LiNK, which attempts 
to quantify the predictive value of putative biomarkers 
and to determine which combinations of markers have 
additive or interactive effects for identifying an indi-
viduals’ likelihood of Li response. A major issue in plan-
ning analyses of biosignatures is that such studies collate 
‘high dimensional data’ (i.e. repeated measures of mul-
tiple putative biomarkers derived from a circumscribed 
clinical sample of a few hundred participants). An entire 
work package (WP7) will address harmonization of mul-
timodal biomarker data, the handling of missing data 
within and across domains, and identification of the most 
appropriate statistical approaches.
Secondary outcomes will focus on the analysis of differ-
ent definitions of Li response and will include e.g. analy-
ses of time to response or ‘mirror-image’ approaches can 
be used to assess changes in illness activity for specified 
time periods before and after initiation of treatment 
Fig. 1 Sequence of assessment of clinical, structural, functional and metabolic markers (see text for details). Pre‑initiation refers to the time 
period between agreement to commence a trial of lithium and actual initiation of medication, and it is expected to average about 2 weeks; most 
post‑initiation measures will be undertaken at approximately week 12 (allowing for titration of lithium dosage & stabilization of plasma levels); 
neuropsychology assessment will be undertaken in individuals with 4 consecutive weeks of euthymia; actigraphy will ideally be include some days 
pre‑lithium initiation, as some analyses will be feasible with a minimum of 3 days of continuous recording; post‑lithium initiation actigraphy may 
be extended for prolonged periods in patients who consent to this; any program for optimizing adherence will commence after approximately 
12 weeks (after stabilization of lithium treatment), when repeated ratings of levels of adherence are available; home‑based salivary lithium 
assessments will only be undertaken in a small subsample of patients who agree to participate in an exploratory pilot study (during the second year 
of follow‑up)
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(such as number of days ill) or intra-individual, day-to-
day symptom variability, etc. Another innovation in the 
R-LiNK study is the inclusion of health economic analy-
ses. Cost-effectiveness has largely been ignored in preci-
sion prescribing studies, but it is important to determine 
whether the introduction of biomarker-driven treatments 
is economically as well as clinically justifiable (Fugel et al. 
2014). Health economics will be examined by construct-
ing simulation models (e.g. mapping current care path-
ways, and then testing the model after incorporating 
relevant findings) to assess the impact of stratification on 
potential costs of treatment for BD-I (of which Li is one 
element) and changes in outcomes (measured in quality 
adjusted life years).
Conclusions
Psychiatry is at a very preliminary stage in its devel-
opment of personalized approaches and stratification 
based on disease mechanisms or drug mechanism of 
action is unfeasible. The current state of our knowledge 
indicates that the search for phenotypes or ‘responder/
non-responder’ subgroups requires a combination of 
systematic exploration of clinical characteristics (such 
as treatment-relevant subtypes within the BD-I diagnos-
tic category), prospective longitudinal monitoring of ill-
ness activity during treatment, alongside the search for 
biomarkers derived from several dimensions (e.g. omics, 
neuro-imaging, actigraphy, etc.). In BD-I, research efforts 
directed towards the identification of biosignatures for Li 
response or tolerability are preferable as it is unlikely that 
a single unidimensional biomarker with robust predic-
tive validity will be found. To date, studies focused solely 
on single clinical or biological markers have explained 
only a small degree of variance. Integrative approaches 
to clinical and multimodal response markers may allow 
a composite ‘prediction algorithm’ to be developed and 
tested in new populations. In addition, this project will 
focus on biological changes induced by Li in each partici-
pant (intra-subject design) to limit the risk of spurious 
findings associated with wide multimodal exploratory 
strategies. Before the findings can be employed to bet-
ter inform the clinical decision-making, it will be neces-
sary to determine which biomarkers can be transferred 
most efficaciously from bench to bedside. This involves 
feasibility of inclusion in routine clinical practice, patient 
acceptability, ease of interpretability of tests, etc., and 
evidence that the costs do not exceed the benefits. Also, 
we recognise that late lithium response (after 2  years) 
will not be detected using the current research frame-
work and additional studies will be needed to capture this 
phenomenon.
The R-LiNK study is an important first step in a pro-
cess that may ultimately help clinicians and patients to 
predict the likelihood of response (or non-response or 
intolerance) to Li prior to or within the first few months 
of initiating treatment. Already, the R-LINK initiative has 
Table 3 Proposed criteria for classifying lithium response
Please note it is not possible to reproduce the full document that will be used by R-LiNK, so the Table provides only examples of the relevant guidance and criteria for 
responder classification
After all the study participants have completed 2 years of prospective follow‑up, clinical response status will be determined by a panel of five experts 
(who are blinded to biomarkers findings). Using a “best estimate” method (Fennig et al. 1994), the panel will review all available clinical data and 
provide a consensus classification for each participant according to one of three categories: (i) good responders (GR), (ii) partial responders (PR), (iii) 
non‑responders (NR). If no clinical follow‑up data are available, the participant will be categorized as unclassifiable (UC)
Overview of procedure:
(i) The panel will first assess clinical outcomes using internationally agreed consensus definitions of clinical recovery, remission, and partial and full 
relapse (Tohen et al. 2009) and review illness activity for the 2 years prior to and 2 years after initiation of lithium treatment. Illness activity is a com‑
posite measure (e.g. incorporating number of syndromal episodes of bipolar disorder (BD), number of days ill or well during a specified time, etc.). The 
percentage change in illness activity will be calculated by estimating the difference in the level of illness activity in the 2 years after lithium initiation 
compared with the 2 years prior to lithium initiation
(ii) Next, the panel will use the evaluation of the clinical outcome to classify the participant in the relevant responder category
For example, for GR:
Classification of response: The expert panel will be asked to classify individuals according to the following steps:
1. All study participants will be classified into the most appropriate responder category irrespective of their exposure to lithium
2. The experts will consider responder status in the context of level of exposure to lithium (e.g. dose, duration of treatment, adherence and serum levels, 
adjunctive treatments, etc.)
3. Further classifications will examine different conceptualizations of response (e.g. time to remission or relapse, etc.) and other outcomes or putative 
changes of interest (e.g. sequence of change of symptoms, etc.)
The individual meets criteria for sustained remission, namely they experience euthymia (defined as a score on the Quick Inventory of Depressive 
Symptoms (qIDS) < 6 and the Bech Rafaelson Mania Scale (BRMS) < 7) for a minimum period ≥ 8 consecutive weeks during the 2‑year follow‑up period 
without evidence of relapse into a syndromal episode of BD at any time after achieving sustained euthymia
AND No additional mood stabilizer medication is prescribed after initiation of lithium treatment
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delivered a large pan-European multidisciplinary col-
laborative network with shared protocols for recruitment 
of clinically representative samples of patients and har-
monized procedures for research; this ensures that the 
network is primed to undertake further studies that can 
refine eligibility criteria for treatment with other mood 
stabilizers and could examine precision prescribing of 
novel drugs in the future.
Additional files
Additional file 1: Appendix S1. Country and location of centres involved 
in R‑LiNK.
Additional file 2: Appendix S2. Proposed list of instruments used for 
baseline clinical assessments and longitudinal monitoring of symptoms, 
medication adherence and lithium response.
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